DNA repair in resistance to alkylating anticancer drugs
The DOI matches its Crossref record.
Abstract
The major critical target of alkylating antineoplastic drugs belonging to the group of methylating and chloroethylating agents is DNA. DNA alkylation lesions can be repaired by the action of alkyltransferase (MGMT) and base excision repair enzymes. The major cell killing and apoptotic alkylation lesions are O6-methylguanine (O6MeG) and O6-chloroethylguanine. O6MeG causes mispairing with thymine which is erroneously processed by mismatch repair (MMR), leading to secondary lesions that potently trigger the mitochondrial apoptotic pathway. Apoptosis induced by O6MeG is a late cellular response that requires cell proliferation to occur. Data are available indicating that DNA double-strand breaks are actively involved as the ultimate trigger of apoptosis. O6MeG and O6-chloroethylguanine are repaired by the specific action of MGMT thus counteracting the killing effects of the lesions. The expression of MGMT is highly variable and is often increased in tumors compared to normal tissue. Determination of MGMT activity in various tumors showed low expression in brain, pancreas and skin and high expression in testicle, breast, colorectal, lung and ovarian tumors. Distribution profiles of MGMT revealed non-random distribution indicating the existence of subpopulations exhibiting low and high activity. Since MGMT is one of the most important factors determining drug resistance to alkylation, strategies have been developed to inhibit MGMT in tumors with the aid of MGMT inhibitors and overexpression of MGMT in healthy, non-target tissue (e.g. blood stem cells) by transferring a mutated form of MGMT inaccessible to inhibition. Targeting MGMT inhibitors to tumors may further enhance the antineoplastic efficiency of alkylating agents. The role of base excision repair, Fos and p53 in drug resistance to alkylation is also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Kaina, B., Christmann, M., Naumann, S., & Roos, W. P. (2007) · DNA Repair · doi:10.1016/j.dnarep.2007.03.008 · Cited by 663
Self-citationThe challenge of drug resistance in cancer treatment: a current overview
Nikolaou, M., Pavlopoulou, A., Georgakilas, A. G., & Kyrodimos, E. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9903-0 · Cited by 600
Calabrese, C. R., Almassy, R., Barton, S., Batey, M. A., Calvert, A. H., Canan-Koch, S., Durkacz, B. W., Hostomsky, Z., Kumpf, R. A., Kyle, S., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh005 · Cited by 487
An overview of cancer multidrug resistance: a still unsolved problem
Lage, H. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8111-5 · Cited by 408
Löhr, M., Klöppel, G., Maisonneuve, P., Lowenfels, A. B., & Lüttges, J. (2005) · Neoplasia · doi:10.1593/neo.04445 · Cited by 343
“scribed in PDAC [52].”
Hermisson, M., Klumpp, A., Wick, W., Wischhusen, J., Nagel, G., Roos, W., Kaina, B., & Weller, M. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03583.x · Cited by 311
Self-citationPoised epigenetic states and acquired drug resistance in cancer
Brown, R., Curry, E., Magnani, L., Wilhelm-Benartzi, C. S., & Borley, J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3819 · Cited by 301
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors
Möllemann, M., Wolter, M., Felsberg, J., Collins, V. P., & Reifenberger, G. (2005) · International Journal of Cancer · doi:10.1002/ijc.20575 · Cited by 278
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities
Kirtane, A. R., Kalscheuer, S. M., & Panyam, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.001 · Cited by 258
DNA repair in neurons: So if they don’t divide what's to repair?
Fishel, M. L., Vasko, M. R., & Kelley, M. R. (2007) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2006.06.007 · Cited by 256
Diagnosis and Treatment of Recurrent High-Grade Astrocytoma
Butowski, N. A., Sneed, P. K., & Chang, S. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7522 · Cited by 172
Wiewrodt, D., Nagel, G., Dreimüller, N., Hundsberger, T., Perneczky, A., & Kaina, B. (2008) · International Journal of Cancer · doi:10.1002/ijc.23219 · Cited by 114
“Since MGMT repairs the primary DNA lesion induced by both groups of agents before they are processed to trigger apoptosis, MGMT is a very important factor in tumor cell resistance toward methylating and chloroethylating anticancer drugs.(12)”
BackgroundSelf-citation
Metadata
- Authors
- Kaina, B., & Christmann, M.
- Venue
- Int. Journal of Clinical Pharmacology and Therapeutics
- Publisher
- Dustri-Verlgag Dr. Karl Feistle
- Published
- 2002-08-01
- Volume
- 40
- Issue
- 08
- Pages
- 354-367
- ISSN
- 0946-1965 (ISSN-L)
- OpenAlex
- W1969885428
- Cited by
- 117
- References
- 0
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.